Lantheus (NASDAQ:LNTH) Price Target Lowered to $122.00 at B. Riley

Lantheus (NASDAQ:LNTH - Free Report) had its price target lowered by B. Riley from $127.00 to $122.00 in a research report released on Friday,Benzinga reports. The firm currently has a buy rating on the medical equipment provider's stock. B. Riley also issued estimates for Lantheus' Q3 2025 earnings at $1.51 EPS.

LNTH has been the subject of a number of other reports. JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective on the stock. Finally, Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Remove Ads

Lantheus Price Performance

Shares of NASDAQ:LNTH traded up $0.96 during mid-day trading on Friday, hitting $98.67. The company had a trading volume of 235,356 shares, compared to its average volume of 934,176. Lantheus has a one year low of $57.92 and a one year high of $126.89. The firm has a fifty day moving average price of $92.67 and a 200 day moving average price of $96.51. The company has a market capitalization of $6.76 billion, a PE ratio of 16.42 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Research analysts expect that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,109 shares of company stock worth $6,110,806. Insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State of New Jersey Common Pension Fund D boosted its stake in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after purchasing an additional 115 shares in the last quarter. Bleakley Financial Group LLC boosted its position in Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after acquiring an additional 129 shares in the last quarter. Avantax Advisory Services Inc. raised its position in shares of Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares in the last quarter. Foundry Partners LLC lifted its stake in shares of Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the period. Finally, UMB Bank n.a. boosted its position in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.